Repare Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results
Reported initial camonsertib data from ongoing Phase 1/2 TRESR and Phase 1b/2 ATTACC clinical trials in a plenary oral presentation at 2023 AACR Annual Meeting Camonsertib combination therapy... | May 9, 2023